Table 3. Survival analysis (significant results).
| Characteristics | Significant P value (<0.05) | |||
|---|---|---|---|---|
| OS | DFS | PFS | MFS | |
| WHO type (C vs. B3 + B2/B3) | 0.021 | |||
| Masaoka-Koga stage | 0.036 | <0.001 | ||
| Masaoka-Koga stage (III + IV vs. II) | 0.009 | <0.001 | ||
| Masaoka-Koga stage (IV vs. II + III) | 0.023 | <0.001 | ||
| Tumor size over median (68.5 mm) | 0.027 | |||
| Surgical approach (minimally invasive vs. open + combined) | 0.031 | |||
| Surgical procedure (biopsy vs. resection of intrathymic tumor vs. thymectomy) | <0.001 | 0.002 | 0.026 | |
| Invasion into lung (yes vs. no) | 0.045 | |||
| Invasion into pleura (yes vs. no) | 0.023 | 0.001 | ||
| Invasion into vessels (yes vs. no) | 0.047 | 0.024 | ||
| Metastasis (yes vs. no) | 0.014 | |||
| Metastasis to pleura (yes vs. no) | 0.002 | |||
| Metastasis to lung (yes vs. no) | 0.008 | |||
| Metastasis to lymph nodes (yes vs. no) | 0.034 | |||
| Metastasis to bone (yes vs. no) | <0.001 | <0.001 | ||
| p21 cytoplasm (yes vs. no) | 0.016 | 0.034 | 0.005 | |
| p21 low, p27 low, p53 high (yes vs. no) | 0.029 | |||
OS, overall survival; DFS, disease-free survival; PFS, progression-free survival; MFS, metastasis-free survival.